ClinicalTrials.Veeva

Menu

Effectiveness Of Tranexamic Acıd Application Wıth Different Doses On Bleeding, Edema And Physician Comfort In Orthognathıc Surgery Patients

B

Bezmialem Vakif University

Status

Completed

Conditions

Edema
Tranexamic Acid
Bleeding
Orthognathic Surgery

Treatments

Drug: Tranexamic acid injection
Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

NCT06301204
21.06.2022-E.67046

Details and patient eligibility

About

The aim of this clinical study conducted in accordance with the information in the literature is to compare the effects of administering tranexamic acid during orthognathic surgery, at different doses. Specifically, investigators aim to compare the effects of administering 1 ampoule IV (approximately 3 mg/kg) and 2 ampoules IV (approximately 6 mg/kg), and evaluate their impact on intraoperative bleeding (ml), surgical duration (min), postoperative swelling, and intraoperative surgical field evaluation (Fromme Scale), by comparing them with control group (applying no drug administration) patient data.

Full description

This prospective double blind clinical study was approved by the Bezmialem Vakif University Clinical Research Ethics Committee (2022-E.6706). All patients were provided detailed explanations of the surgical procedure and potential adverse events, underwent preoperative anesthesia assessments, and provided informed consent. A total of 60 patients were included in the study and were randomly assigned to three groups: Study Group 1 (N=20), Study Group 2 (N=20), and Control Group (N=20). In Study Group 1, patients received local anesthesia prior to bimaxillary osteotomy, followed by intravenous administration of 250 mg / 2.5 mL tranexamic acid before starting with the incision. In Study Group 2, patients also received local anesthesia before bimaxillary osteotomy, followed by intravenous administration of 250 mg / 2.5 mL tranexamic acid for le fort 1 and, a second dose of 250 mg / 2.5 mL tranexamic acid was administered for beginning of the sagittal split osteotomy. The Control Group, Group 3, did not receive any medication before or after surgery. All patients underwent bimaxillary surgery using the same surgical technique and same surgical team.

Enrollment

60 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with class 2 or class 3 dentofacial malformation who are planned to undergo bimaxillary orthognathic surgery.
  2. Patients who have not had orthognathic surgery before
  3. Patients without cleft lip and palate
  4. Patients without systemic bleeding diets

Exclusion criteria

  1. Having a systemic disease that affects general health status
  2. Presence of a malignant disease in the head and neck region
  3. Patients who have previously undergone orthognathic surgery
  4. Patients with any bleeding disorders

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 3 patient groups, including a placebo group

control group
Placebo Comparator group
Description:
control group patient give no drug administration during bimaxillary orthognathic surgery.
Treatment:
Drug: Saline
group 1(intravenous administration of 250 mg tranexamic acid)
Active Comparator group
Description:
group 1 (TRANEXEL 250 mg/5 mL) patients administered 250 mg tnx acid during the whole bimaxillary orthognathic surgery
Treatment:
Drug: Tranexamic acid injection
group 2 (intravenous administration of 500 mg tranexamic acid)
Active Comparator group
Description:
group 2 (TRANEXEL 250 mg/5 mL) patients administered 500 mg tnx acid during the whole surgery.
Treatment:
Drug: Tranexamic acid injection

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems